Search Results 91-100 of 13960 for Moderate acute malnutrition

1. A Study Of CTX-712 In Relapsed/Refractory Acute Myeloid Leukemia And Higher Risk Myelodysplastic Syndromes - Mayo Clinic

   A Study Of CTX-712 In Relapsed/Refractory Acute Myeloid Leukemia And Higher Risk Myelodysplastic Syndromes ... Known moderate to severe and clinically significant ...

2. A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease - Mayo Clinic

   The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely ...

3. Adults With Acute Infection - Mayo Clinic

   The overall objective of this observational study is to characterize epidemiological, clinical, and biological features of adult patients hospitalized with ...

4. Specialty Compared To Oncology Delivered Palliative Care For Treating Acute Myeloid Leukemia - Mayo Clinic

   ... acute myeloid leukemia (AML). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

5. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Study Of SHP647 As Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   ... Moderate To Severe Ulcerative Colitis (FIGARO UC 302). Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic ...

6. A Study To Assess Disease Activity And Safety Of Subcutaneous Lutikizumab (ABT-981) In Adult Participants With Moderate To Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy And Who Are Naïve To Biologic Therapy - Mayo Clinic

   ... Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti‑TNF Therapy. Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects ...

7. A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ - Mayo Clinic

   ... moderate to severe objective evidence of cardiovascular disease * Myocardial infarction or stroke less than or equal to 6 months prior to registration

8. Pancreatitis and Acute Outcomes Research: Vijay P. Singh

   These outcomes range from a short, mild self-limited illness to severe devastating disease resulting in multisystem organ failure, infectious complications ...

9. Acute Stroke Or Transient Ischaemic Attack Treated With Aspirin Or Ticagrelor And Patient Outcomes - Mayo Clinic

   About this study. The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose ...

10. Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma - Mayo Clinic

    ... moderate to severe melasma. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...